Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.320
-0.030 (-2.22%)
Mar 31, 2025, 10:43 AM EDT - Market open
Quince Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Quince Therapeutics stock have an average target of 8.00, with a low estimate of 4.00 and a high estimate of 11. The average target predicts an increase of 506.06% from the current stock price of 1.32.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Quince Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 → $4 | Strong Buy | Maintains | $12 → $4 | +203.03% | Mar 25, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $10 | Buy | Initiates | $10 | +657.58% | Mar 24, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +809.09% | Feb 5, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +809.09% | Jan 2, 2025 |
| Brookline Capital | Brookline Capital | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +581.82% | Dec 18, 2024 |
Financial Forecast
Revenue This Year
n/a
from 416.19M
Revenue Next Year
n/a
EPS This Year
-0.68
from -1.31
EPS Next Year
-0.64
from -0.68
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 57.9M | ||
| Avg | n/a | n/a | 40.0M | ||
| Low | n/a | n/a | 22.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.33 | -0.15 | 0.05 | ||
| Avg | -0.68 | -0.64 | 0.05 | ||
| Low | -0.87 | -1.04 | 0.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.